FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment
PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving FDA acceptance for the New Drug Application ... Read More
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. ... Read More